Actively Recruiting
PD-L1 Targeting Molecular Imaging of Solid Tumors
Led by Peking University Cancer Hospital & Institute · Updated on 2024-08-19
20
Participants Needed
1
Research Sites
171 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.
CONDITIONS
Official Title
PD-L1 Targeting Molecular Imaging of Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged over 18 years old; ECOG performance status 0 or 1
- Diagnosed with gastrointestinal tumors
- Has at least one measurable target lesion according to RECIST V1.1
- Life expectancy of 12 weeks or more
You will not qualify if you...
- Significant liver or kidney dysfunction
- Pregnant or planning to become pregnant
- Unable to remain still for at least half an hour
- Refusal to participate in the clinical study
- Suffering from claustrophobia or other mental health conditions
- Any other condition deemed unsuitable by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
H
Hua Zhu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here